Interview with Sven Dethlefs, CEO, TEVA Germany
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Address: Gottfried-Hagen Str. 62
D-51105 Köln,Germany
Tel: +49 (0)2 21- 46 02 08 00
CEVEC focuses on the development of a platform expression technology based on specific human cell lines (CAP cell lines) and on the development of selected biopharmaceuticals. CEVEC was founded in 2001 by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work they had experienced a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors.
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
See our Cookie Privacy Policy Here
